For people with type 2 diabetes and diabetic kidney disease, it is recommended to use a sodium-glucose cotransporter 2 inhibitor to slow the progression of cardiovascular events and chronic kidney disease in patients with estimated glomerular filtration rate ≥ 20 mL/min/1.73 m2 and urinary albumin ≥ 200 mg/g creatinine [18, 36, 69]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.